- 43% of Latino people reported symptoms of Long COVID in a new survey study published in Journal of General Internal Medicine. The survey included the responses of 1,500 participants in Washington state who had confirmed COVID-19 cases between 2020 and 2022, and used the World Health Organization definition of Long COVID. The researchers also found that women and middle aged adults were more impacted by the disease. “The community we surveyed were in frontline positions,” author Leo Morales told the Yakima Herald. “There were high levels of exposure…so there was a lot of transmission to vulnerable people, and they had relatively little access to care.”
- A case series for Long COVID using a combination of Paxlovid, valacyclovir (Valtrex) and celecoxib (Celebrex), was recently published in Frontiers of Immunology. The series, which did not have a placebo group, was originally shared as a preprint last year, and included 27 people with Long COVID. The authors concluded that the protocol may help address both viral persistence as well as viral reactivation, two of a handful of leading theories of Long COVID. Study author David Putrino said during PolyBio’s fall 2025 symposium that the center he leads at Mount Sinai is planning a clinical trial of the protocol.
- A new phase II clinical trial for Long COVID was recently announced in the Netherlands. Researchers arestudying the drug Sonlicromanol (or, KH176), a clinical-stage oral drug compound for primary mitochondrial diseases. 80 participants with Long COVID who have post-exertional malaise (PEM) will take the drug, or a placebo, for 13 weeks. The study is not yet recruiting.
